Gindarine composition. RU patent 2372912.

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine, namely to an oral gindarine tranquiliser. There is offered composition for capsule containing as an active substance, gindarine in the form of gindarine hydrochloride, and an adjuvant chemically inert to the active substance and physiologically acceptable or number of adjuvants enabling prolonged release of gindarine hydrochloride. The composition represents granules, or mixed powders, or mixed granules and powder, or liquid, or soft form. As adjuvants, the composition contains an excipient, alone or combined with a disintegrant, or an antifriction substance, or a binding substance, or mixture thereof. The composition representing the liquid form - suspension, or the soft form - gel, as adjuvant contains a liquid base, alone or mixed with a thickener or a preservative, or mixture thereof.

EFFECT: according to the invention the composition is characterised by prolonged release of gindarine from oral dosage capsular form.

10 cl, 18 ex

IPC classes for russian patent Gindarine composition. RU patent 2372912. (RU 2372912):

A61P25/22 - Anxiolytics

A61K9/52 - Sustained or differential release type

A61K31/4375 -

Another patents in same IPC classes:

Method of obtaining pharmaceutical composition for oral introduction possessing improved bioaccessibility of biologically active effective medicinal substance, and pharmaceutical composition obtained by said method / 2370268
Method of obtaining tablets containing crystalline-form-free alprazolam, includes at preliminary stage of granulation operation obtaining alprazolam solution in pharmacologically acceptable solvent together with crystallisation-inhibiting agent, formed by mixture of binding substance and from 20 to 60% wt of total amount of lubricating substance, impregnation with obtained solution of mixture of diluent and 25% reticular carboxymethylcellulose as disintegrating agent until homogeneous granulated mass is obtained and grinding of obtained granulated mass, preliminarily dried, until grinded granulometrically homogeneous mass is obtained. At the second stage of granulation operation, 100% of remaining lubricating agent and remaining reticular carboxymethylcellulose and aromatising additives are added to dried and grinded mass, obtained at preliminary stage of granulation operation; aromatised mass is finally mixed and pressed. Non-crystalline state of alprazolam improves its solvability and bioaccessibility.

Imidazole iii derivatives / 2360911
In general formula I R1 stands for haloid, lower alkyl; R2 stands for lower alkyl or C3-C6-cycloalkyl; R3 stands for lower alkyl, C3-C6-cycloalkyl, -(CH2)n-C3-C6-cycloalkyl, (CH2)n-CN or -(CH2)n-O-(lower)alkyl, (lower)alkoxyaryl, Fn-R5, where R5 is lower alkyl or lower alkenyl; n takes values 1, 2 or 3; R4 is hydrogen or CH2R5, where R5 is hydrogen, C1-C6-alkyl, C3-C12-cycloalkyl; as well as its pharmaceutically acceptable salts. Invention also relates to methods of obtaining formula I compounds, medication based on formula I compound and its application.

Oral gindarine medicine and production method / 2360675
Invention refers to chemical-pharmaceutical industry and medicine, namely to oral gindarine medicine characterised as a tranquilizer. Said medicine contains gindarine hydrochloride as an active material and auxiliary components and represents a solid gelatinous capsule. Gindarine is included as a compound of the mass filling capsules as mixed powders of gindarine and auxiliary components or as a granulated material. As the auxiliary components, the medicine contains bulking agent either alone, or combined with a disintegrant or antifriction material or with their mixture. There is also provided method of production of specified oral medicine.

Method of treatment or prevention of central nervous system diseases by means of compounds possessing selectivity with respect to alpha-3-subunit of benzodiazepine receptor / 2354377
Inventions relate to medicine, in particular to psychiatry and can be used for treatment or prevention of anxiety state or anxiety state episode. Pharmaceutical composition includes efficient amount of ELB 139 (1-(4-chlorphenyl)-4-pyperidinoimidazolin-2-on) or 1-(4-methoxyphenyl)-4-pyperidinoimidazolin-2-on, and method includes introduction to patient of efficient amount of ELB 139 (1-(4-chlorphenyl)-4-pyperidinoimidazolin-2-one) or 1-(4-methoxyphenyl)-4-pyperidino imidazolin-2-one.

Glycosaminoglycans for emotional insanity treatment / 2353371
There is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.

Application of carbamazepine derivatives for treating excitation in patients suffering from dementia / 2351338
Invention relates to field of medicine and pharmacology and concerns application of carbamazepine derivatives of formula (1) for treating excitation in patients, method of excitation treatment, pharmacologic composition for excitation treatment, combination of formula (1) compound with nootropic agent for excitation treatment, application of combination for preparation of medication for treating excitation and industrial packing.

Method of treatment of neurosis of obsessional conditions / 2350331
Invention concerns medicine, namely to psychiatry, and can be used at treatment of patients with a neurosis of obsessional conditions. For this purpose within 20 days pharmacotherapy is performed, including Diazepamum introduction, Mexidol and Tymogene. Thus Tymogene is administered intramusculary in a dose of 0.1-0.125 mg once in two days in amount of 10 injections. Simultaneously with pharmacotherapy within the first 15 days hyperbaric oxygenation is performed.

Method of hysterical neurosis treatment / 2350330
Invention concerns medicine, namely psychiatry, and can be used at treatment of patients with a hysterical neurosis. For this purpose pharmacotherapy is performed within 20 days including administration of 0.5% solution of Diazepamum intramusculary, 2-3 ml a day, Mexidol, 0.01% of T-activin solution 1-1.2 ml intramusculary, ten injections in a day. Thus Mexidol during the first 10 days is administered in the form of 5% solution of 2-3 ml a day intravenously driply, and the next 10 days in tablets in a daily dose of 100-125 mg. Simultaneously with pharmacotherapy within the first 10 days of 1 times a day perform hyperbaric oxygenation with an overpressure of 0.8-1.0 atmosphere at rate of a compression and decompression of 0.1 atmospheres in a minute, the isopressure period makes 40 minutes.

Agent possessing anxiolythic action, on basis of hydrogenated pyrido (4,3-b) indoles (versions), pharmacological agent on its basis and way of its application / 2338533
Application of hydrogenated pyrido (4,3-b) indoles of the formula (1) or formula (2) as an agent possessing anxiolythic action, a pharmacological agent on its basis and a way of treatment and prevention of stresses, psychic tension, neurosises, obsessional pavors and their consequences is offered.

Method for premedicating cardiovascular abnormality patients within the framework of out-patient visit to dentist / 2321335
Method involves estimating patient health state condition based on diagnostic cardiac rhythm variability data as intersystolic interval duration mean square deviation. The diagnostic index being equal to or less than 20 ms, Tophysopam is to be per os introduced at a dose of 50 mg 30 min before surgical intervention. The diagnostic index value being greater than 20 ms and less than 50 ms, Tophysopam is to be introduced at a dose of 25 mg 30 min before surgical intervention.

Composition for making dosage form with prolonged effect and method of making said form / 2363451
Composition contains a pharmacological agent, water-soluble polymer and a fatty base. The pharmacological agent is chosen from a group, containing diclofenac, acetylsalicylic acid, paracetamol, ibuprofen, ketorolac, pentoxifeylline and ciprofloxacin. The water-soluble polymer is chosen from a group, containing hydroxypropylmethicellulose, polyvinylpyrrolidone, egg white, sodium caseinate, milk protein, guar gum, sodium alginate, pectin, chitosan acetate, polygalactomannan, dextran or their mixture. The fatty base relates to oils consumed by human beings, which melt at temperature between 30 and 36°C and chosen from a group containing: cocoa bean oil, coconut oil, milk fat, pork fat, hydrofat or their mixture. The said pharmacological agent and water-soluble polymer are contained in the composition in form of a non-covalent complex.

Capsule for medicinal and-or vitamin preparations / 2362550
Capsule for medicinal and-or vitamin preparations contains covers encapsulated one in another with walls soluble in a human body, medicinal and-or vitamin preparations located between walls, differs that the covers which walls have different time fastness to dissolution, are located in the following sequence: a gelatin cover; a cover from the gelatin processed in pairs of formic aldehyde; a cover from acetyl phthalyl cellulose; a cover from ethyl cellulose with microporous structure.

Medicinal forms on basis of biphosphonates / 2359678
Invention concerns medicine area, namely to peroral medicinal forms on a basis of biphosphonates, containing safe and effective quantity of the pharmaceutical composition containing biphosphonate, chelated agent and an agent for effective delivery of a pharmaceutical composition in the bottom gastroenteric tract of a mammal, and also pharmaceutically active biphosphonate absorption together with nutrition or drinks or without them. The present invention essentially reduces interaction between biphosphonates and nutrition or a drink, which (interaction) leads to that active biphosphonate component is not accessible to absorption. The final peroral medicinal form can be accepted both with food, and without it. Further, the present invention influences delivery biphosphonate and chelated agent in a bottom of GI tract, essentially reducing irritation of top of the GI tract, bound with biphosphonate therapy.

Capsules containing reactant pellets differing with reactant release profiles / 2356540
Invention refers to medicine. There is disclosed capsule containing various reactant pellets differing with reactant release profile in gastrointestinal tract and containing at least two various reactants specified from vitamin complexes, mineral matters, microelements, unsaturated fatty acids, amino acids and/or vegetative extracts and substances. Differing reactant release profiles are related to fast, average and/or slow dissolution of reactant pellets. Such controlled reactant release provides stable absorption in various and optimum gastrointestinal parts.

Medicinal composition containing flupirtin, with controllable release of biologically active substance / 2352338
Invention concerns the solid medicinal composition, including flupirtin or its physiologically comprehensible salts as biologically active substance. At least, one part of flupirtin exists as preparative ready form with the slowed down liberation of the active component. The preparative ready form contains the pressed forms flupirtin, which are preferably in regular intervals covered by a prolonging component. Form pressing of flupirtin is characterised by the size of particles of 160-800 mcm, in bulk volume less than 5 ml/g and preferably are spherical or close to spherical. The prolonging component provides diffused-controllable flupirtin release and preferably includes polymer or a copolymer from acrylic acid, derivatives of acrylic acid, methyl-acrylic acid and-or derivatives of the methyl-acrylic acid, or their admixtures.

Electro-spinned amorphous pharmaceutical compositions / 2331411
Invention relates to medicine, particularly to electro-spinning, i. e. polymer nano-fibres obtaining process from solution or melt due to the electric force action, applying to production of stable solid dispersions of amorphous drug substances in polymer nano-fibres.

Method for production of micronised powder of incapsulated organic drug substance with slow dissolution rate / 2331409
Method consists in as follows: initial organic drug substance and auxiliary low-molecular organic ingredient, serving as a matrix to prolongate the release of the former substance into aqueous solution, are simultaneously and separately vaporised in rarefied neutral gas medium. The simultaneously obtained vapours of the mentioned substance and the matrix ingredient are then co-condensed on deposition surface. The angle between deposition velocity vectors of the mentioned drug substance and the matrix-forming ingredient, and inclination of the angle bisector to deposition surface are 5-170° and 10-90° respectively. Microcapsulation is effected or at positive temperatures of deposition surface during co-condensation process, or at negative temperatures of deposition surface during the co-condensate obtained warming to positive temperatures.

Lamotrigine-based compositions of prolonged release / 2325163
Invention involves compositions of lamotrigine and its pharmaceutically acceptable derivative of prolonged release. Composition includes: 1) nucleus with lamotrigine or its pharmaceutically acceptable derivative; 2) outer coating of nucleus thickness of which is selected so that it is actually resistant for ambient liquids and actually resistant for release of lamotrigine or its pharmaceutically acceptable derivative, and 3) mentioned outer coating has one or more pores from outer face of coating through essentially all the coating without penetration to mentioned nucleus enabling release of lamotrigine or its pharmaceutically acceptable derivative from nucleus into ambient liquid. Mentioned pores have area or integrated area from approximately 10 to approximately 60% of front-face area of mention composition. And release of lamotrigine or its pharmaceutically acceptable derivative is performed essentially trough mentioned pores. Outer surface at that dissolves in the event ambient pH exceeds 5. Composition provides prolonged release of lamotrigine by two procedures: slower release due to initial release of lamotrigine through the pore, and faster release in further step due to dissolving of outer coating.

Multi-component graduated pharmaceutical form / 2325153
Invention is related to a multi-component graduated pharmaceutical form capable of holding medicine, which can be released in a controlled manner in the gastrointestinal tract, consisting of body of, for example, polymer material, which ensures immediate, delayed, or impulse release, at least one cavity with an entrance, and polymer coating which ensures immediate, delayed, or impulse release, is welded to the body, covers the entrance, and is 20-300 micron wide. The invention is also related to production of such graduated pharmaceutical form.

System for prolonged release of soluble drug / 2322263
Invention relates to drugs and concerns sustained-release oral compositions. Agent comprises micelle-forming water-soluble main drug showing a positive charge at physiological pH value, polymer showing an opposite charge chosen from group consisting of polyacrylic acid, carboxymethylcellulose, xanthane gum, hellane gum, guara gum, dextran-sulfate and carragheenan, polyethylene oxide and if necessary a hydrophilic base. Also, invention proposes a method for sustained-release of micelle-forming drug.

Polymorphic analog therapy (versions) / 2372911
Invention refers to medicine, namely to therapy, and can be used for treating consequences of microstroke. The method involves sequential introduction throughout the day of medical products in a single dose: mildronat, pyracetam, picamilonum and vinpocetine. Said introduction is performed during 15 days. Then these preparations are introduced in 1/4 single dose simultaneously 4 times a day during 15 days also.